Vivos Therapeutics Inc Ordinary Shares VVOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Therapeutics Announces Material Debt Reduction
Trading Information
- Previous Close Price
- $0.10
- Day Range
- $0.07–0.10
- 52-Week Range
- $0.07–2.69
- Bid/Ask
- $0.08 / $0.08
- Shares Outstanding
- 33.61M
- Market Cap
- $1.65M
- Volume/Avg
- 17,705 / 14M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 268
- Website
- https://www.vivos.com
Valuation
Metric | VVOS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.07 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VVOS |
|---|---|
Quick Ratio | 0.16 |
Current Ratio | 0.21 |
Interest Coverage | — |
Quick Ratio
VVOS
Profitability
Metric | VVOS |
|---|---|
Return on Assets (Normalized) | −100.48% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −202.06% |
Return on Assets
VVOS
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|bnNzkjZ | LOCK|Ly$<m | $186B | |||
| Medtronic PLC MDT | LOCK|<L#R&? | LOCK|&?ll | $132B | |||
| Stryker Corp SYK | LOCK|LX$$^Q%? | LOCK|^#N | $118B | |||
| Boston Scientific Corp BSX | LOCK|ZY@Ls!% | LOCK|@<>@ | $63B | |||
| Edwards Lifesciences Corp EW | LOCK|^FgRwv!w | LOCK|@^D?V | $62B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|X@m&?yt | LOCK|y<N | $38B | |||
| DexCom Inc DXCM | LOCK|b%n<^r? | LOCK|%$!$ | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|lt | LOCK|pc | $30B | |||
| Steris PLC STE | LOCK|mCPyG@f | LOCK|$%fR | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|h#p!^x# | LOCK|p% | $19B |